Add time:09/01/2019         Source:sciencedirect.com

Analytical methods were developed and validated for the determination of ENLOPLATIN (cas 111523-41-2) (an anticancer agent) in plasma by reversed-phase LC and for platinum (an elemental component of enloplatin) in plasma, plasma ultrafiltrate (PUF) and whole blood by flameless atomic absorption spectrometry (FAAS). The LC procedure involved protein precipitation with dilute perchloric acid. The supernatant was mixed with sodium phosphate buffer and injected into the LC system. A C18 or a cyano column was used, depending on sample matrix, with UV detection at 230 nm. The LC method was linear from 0.50 to 50.0 μg ml−1. Inter-day and intra-day precision (RSD%) and accuracy (relative error%) were <±14%. The FAAS procedure utilized a graphite furnace, a hollow cathode platinum (Pt) lamp, and Zeeman background correction. An aliquot of plasma, PUF, or whole blood was mixed with a solution of Triton X-100 and Antifoam-B and injected into the FAAS system. The FAAS method showed goodness of fit from 0.05 to 10.0 μg Pt/ml. Inter-day and intra-day precision and accuracy were <±15%. The methods were developed to support pharmacokinetic studies in humans, dogs and rats.

We also recommend Trading Suppliers and Manufacturers of ENLOPLATIN (cas 111523-41-2). Pls Click Website Link as below: cas 111523-41-2 suppliers